[{"pageContent":"Pharmaceutical and Biotech Policy \nIssues, Part 2\nPUBPOL 2350\nNovember 2, 2023","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":1,"lines":{"from":1,"to":4}}}},{"pageContent":"2","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":2,"lines":{"from":1,"to":1}}}},{"pageContent":"3","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":3,"lines":{"from":1,"to":1}}}},{"pageContent":"4","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":4,"lines":{"from":1,"to":1}}}},{"pageContent":"5","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":5,"lines":{"from":1,"to":1}}}},{"pageContent":"6","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":6,"lines":{"from":1,"to":1}}}},{"pageContent":"7","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":7,"lines":{"from":1,"to":1}}}},{"pageContent":"8","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":8,"lines":{"from":1,"to":1}}}},{"pageContent":"9\nAny Current Events? \nAll Prelim #1 regrades have been completed","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":9,"lines":{"from":1,"to":3}}}},{"pageContent":"Today’s Topics\n1.\nMarketing: \nWhy do biotech and pharmaceutical firms spend so \nmuch money marketing drugs?\n2.\nDrug Prices\n: Why are prescription drug prices so much lower in \nother high\n-\nincome countries than in the U.S.?\n3.\nPolicies to Reduce U.S. Drug Prices\n: discuss the impact of allowing \nthe U.S. government (i.e., Medicare) to negotiate drug prices with \nbiopharmaceutical firms, beginning in 2026.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":10,"lines":{"from":1,"to":16}}}},{"pageContent":"Marketing Spending Has Declined in Past Decade But Is \nStill Focused on \nPhysicians\n, Not Patients\n11.4\n29.9\n32.3\n29.3\n29.9\n1996\n2005\n2008\n2010\n2016\nIndustry Spending, $ Billions\n \n \n  \n$ Billions\nDetailing\n$5.6\nSamples\n$13.5\nMD Meetings\n$1.0\nDirect\n-\nto\n-\nconsumer\nadvertising\n$9.6\nOther\n$0.2\nTotal\n$29.9\nSource: SK&A, \n2012 U.S. Pharmaceutical Promotion Spending; Schwartz and Woloshin, JAMA, 2019\n.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":11,"lines":{"from":1,"to":39}}}},{"pageContent":"What is Detailing?","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":12,"lines":{"from":1,"to":1}}}},{"pageContent":"John Oliver’s Take","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":13,"lines":{"from":1,"to":1}}}},{"pageContent":"Why Do Pharmaceutical\n \nFirms Spend\n$30 Billion Per Year on\n \nMarketing/Advertising?","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":14,"lines":{"from":1,"to":6}}}},{"pageContent":"Product Life Cycle: Revenue \nUsually \nGrows \nSteadily \nOver an\nExtended \nTime, Then Falls \nShar\np\nly\n \nWhen the Patents Expire\nSource: DiMasi and Grabowski, 2012.\n-100\n-50\n0\n50\n100\n150\n200\nMillions of 2000 Dollars\nYear\nDrug\nLaunch\nIt often takes \n10 years for \ndrug sales to \npeak as MDs \nand patients \nlearn\n \nabout \nthe new drug\nRed line: profit of the drug\nLosses when\ndeveloping drug","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":15,"lines":{"from":1,"to":36}}}},{"pageContent":"The Slow Uptake\nSource: Berndt, \nHealth Affairs\n, 2001.\nExperience Goods: \nPharmaceutical drugs are \nexperience goods\n; \nphysicians and patients need to \ntry\n \nthe product \nin order to\n \ndetermine \nwhether it’s valuable to them.\nCompanies that make experience goods tend to market \nheavily \nin order to\n \nprovide \ninformation\n \nabout the value of \ntheir product. (But does marketing also \npersuade\n \npeople\n \ndo\n \nbuy/try something\n \nthey\n \nshould\n \nnot?\n)\nExperience Goods \nMakers \nHeavy Marketing\nPotential Value of \nProduct\nImage Source: https://\nwww.iconfinder.com\n/\nrasulh","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":16,"lines":{"from":1,"to":48}}}},{"pageContent":"Conclusions, Part 1 of Pharma\n▪\n \nDeveloping a drug takes a long time, is expensive, and \n   \nis not guaranteed to work.\n▪\n \nPatents allow pharmaceutical firms that successfully launch \n   \na new drug to make $ on it, thus providing incentives for\n   \nthem to incur the uncertainty and large expenditures involved.\n▪\n \nGeneric drugs, which have relatively low prices, now account\n   \nfor 91% of all prescriptions.\n▪\n \nFirms market to physicians and patients to convey information\n   \nabout the drugs, so they will try them \n(\ni.e., \nexperience \ngoods).\n▪\n \nMarketing is especially important because once the patent \n   \nexpires, \nalmost all patients shift to a \ngeneric \nversion\n.\n▪\n \nThe government closely regulates the drug development, \n   \nmanufacturing, and marketing processes.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":17,"lines":{"from":1,"to":41}}}},{"pageContent":"Percentage of Personal Health Care Spending by Type of Service\n39%\n44%\n47%\n41%\n37%\n37%\n22%\n22%\n22%\n26%\n25%\n24%\n4%\n7%\n10%\n11%\n11%\n9%\n11%\n9%\n6%\n7%\n11%\n11%\n23%\n18%\n16%\n15%\n16%\n19%\n1960\n1970\n1980\n1990\n2000\n2021\nOther\nRx Drugs\nPhysician \nServices\nHospitals\nHome care/\nnursing home\nSource: CMS and Hartman et al., 2023.\nPharmaceutical Expenditure Share Has Almost Doubled\nOver the Past 40 Years","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":18,"lines":{"from":1,"to":47}}}},{"pageContent":"Protease Inhibitor Cocktails Reduced HIV Mortality Sharply\nSome of the Increased Use of Prescription \nDrugs Has Clearly Improved Health\nCovid vaccines are another good example","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":19,"lines":{"from":1,"to":4}}}},{"pageContent":"Other High\n-\nIncome Countries Spend Much Less Than the \nU.S. on Prescription Drugs, Largely Due to Lower \nPrices\nPer Capita Prescription Drug Spending, 2022\n$402\n$517\n$595\n$748\n$681\n$766\n$1,043\n$914\n$836\n$1,432\nDenmark\nUK\nSpain\nItaly\nAustralia\nFrance\nGermany\nCanada\nJapan\nUSA\nSource: Organization for Economic Cooperation and Development, OECD, 2023.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":20,"lines":{"from":1,"to":27}}}},{"pageContent":"Drug prices in the U.S. are much higher than in peer countries, 2018.\nSource: Mulcahy et al., 2021.\nU.S. Pays Much Higher Prices for Drugs Than Other Countries","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":21,"lines":{"from":1,"to":3}}}},{"pageContent":"Why are drug prices so much lower in \nEurope, Japan, and Canada than the \nUnited States?\nWhat would happen if the U.S. \ngovernment regulated prices like \nEurope and Japan do, or if we had a \nsingle payer system?","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":22,"lines":{"from":1,"to":7}}}},{"pageContent":"Higher U.S. Drug Spending Driven by Higher \nPrices\n \nand \nGreater Use of \nNew\n/Expensive Drugs but Not a Greater \nQuantity\n \nof Prescriptions\nPrices Set in Market \nU.S. drug prices are set in the \nmarket\n \nby pharmaceutical \nfirms, who negotiate with \nhundreds\n \nof private health \ninsurers (but not the U.S. government, by law, until 2026).\nInternationally, Firms Negotiate with One Entity\nA major reason prescription drug prices are about 60% lower \nin other developed countries is that pharma firms negotiate \nwith \none entity\n \n(the government), which gives the \ngovernment negotiating power via a take\n-\nit\n-\nor\n-\nleave\n-\nit threat. \nJapan and EU Policies \nEU and Japan also have policies that favor the \nuse of older less expensive drugs, which creates\nadditional negotiating power for a single \npayer/insure\nr\n.\nImage Source: https://\nwww.iconfinder.com\n/\nMakoto_msk","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":23,"lines":{"from":1,"to":47}}}},{"pageContent":"24\nInflation Reduction Act (2022) Health Components \nSource: Hwang et al., \nJAMA\n, August 19, 2022.\n.\n➢\nFor first time, \nMedicare\n \n(federal\n \ngovernment)\n \ncan negotiate\n     \nprices of prescription drugs for 10 small\n-\nmolecule drugs \n     \nbeginning in 2026, and 70 eventually.  35 biologics starting in\n     \n2028.\n➢\nReduced prices can occur 9 years after a small\n-\nmolecule drug is \n     \nlaunched, or 13 years after a biologic is launched.\n➢\nFirst 10 drugs just announced.  They account for 20% of \n     \nMedicare \nPart D\n \nspending.\n➢\nVery strong penalties if the 2 parties cannot agree on a price.\n➢\nMedicare is supposed to consider whether a drug addresses an\n     \nunmet need, represents a therapeutic advance, its R&D costs,\n     \nand prior federal funding received.\n➢\nEstimated to save taxpayers $25 billion per year.\n➢\nSeveral biopharmaceutical firms are suing, arguing the IRA is\n     \nunconstitutional.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":24,"lines":{"from":1,"to":50}}}},{"pageContent":"25\n➢\nThere are some drug types that cannot be subject to price\n     \nnegotiation (e.g., drugs approved for only a single rare disease).\n➢\nPharmaceutical firms must offer additional discounts if they \n     \nraise their drug prices faster than inflation.\n➢\nBeginning in 2025, Medicare beneficiaries cannot pay more \n     \nthan $2,000 per year out\n-\nof\n-\npocket on prescription drugs.\n➢\nMain concern regards possible dis\n-\nincentives to innovate for\n     \nan already\n-\napproved drug (such that the “clock has started\n     \nticking”) \nwhere the firm is \nconsidering \nspending\n \nR&D\n \nmoney\n     \nto develop \na \nfollow\n-\non \nindication\n \nto the first indication\n.\nMore on the Inflation Reduction Act (IRA) \nSource: Hwang et al., \nJAMA\n, August 19, 2022.\n.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":25,"lines":{"from":1,"to":49}}}},{"pageContent":"Discussion\nWhat Impact is Medicare Price Negotiation Likely to Have on:\n1.\nR&D spending generally, drug approvals, and investment in \nfollow\n-\non\n/second\n \nindications?\n2.\nPrescription drug prices paid by:\na)\nPrivate insurers in the U.S.?\nb)\nOther high\n-\nincome countries?","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":26,"lines":{"from":1,"to":18}}}},{"pageContent":"Regulating the Prices of Prescription Drugs in the U.S. \nInvolves a Tradeoff\nSet Prices Below Market Value \nThe U.S. government will save substantial money \ntoday\n \non prescription drugs by \nsetting Medicare prices below today’s “free market” prices.  \nPharmaceutical Firms Response \nDrug firms may respond by investing less in research and development of new \ndrugs, and further indications of already\n-\napproved drugs, because the expected \nprofit of a drug/indication will be lower.\nResult\n5\n-\n10 years from now\n, fewer new drugs \nmight\n \nbe launched as a result, and/or \nfewer follow\n-\non indications.  CBO is estimating a modest effect on innovation.\nWhen prices to Medicare are cut, what is the value of tomorrow’s \n“lost” drugs/indications compared to today’s savings? \nWill other high\n-\nincome countries raise their prices to compensate \nfor the diminished incentive to \ndevelop\n \nnew\n \ndrug\ns\n?\nKey Policy Questions","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":27,"lines":{"from":1,"to":39}}}},{"pageContent":"Pharma \nConclusions\n, Part 2\n▪\n \nPrescription drug spending has increased \n   \nsubstantially over the past 35 years.\n▪\n \nHealth has improved because of \n(some of) the \nnew \ndrugs.\n▪\n \nPharmaceutical prices in most high\n-\nincome countries \n   \nare lower than the U.S. due to government negotiation\n   \nand regulation.\n▪\n \nControlling/regulating prices in the U.S. will involve a\n   \ntradeoff between saving money now and having less \n   \ninnovation (and presumably worse health) in the future.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_Part_2_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231102093924-04'00'","ModDate":"D:20231102093924-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-11-02T09:39:24-04:00","xmp:modifydate":"2023-11-02T09:39:24-04:00","xmpmm:documentid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524","xmpmm:instanceid":"uuid:9BFE8BD0-DD27-4F16-B5DC-1B0F40766524"}},"totalPages":28},"loc":{"pageNumber":28,"lines":{"from":1,"to":30}}}}]